Q-omics provides the consensus-scored RPSAP58 profile across patient tissues and cancer cell-line models. RPSAP58 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RPSAP58 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, RPSAP58 RNA expression shows 12,093 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight CESC, COAD, and DLBC as cancer lineages where RPSAP58 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPSAP58 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPSAP58 survival associations across molecular data types. RPSAP58 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPSAP58 RNA expression–survival associations across cancer types. High RPSAP58 expression shows unfavorable associations in LIHC and STAD, but favorable associations in CESC, BLCA, LUSC and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .008). Together, the overview and detailed table identify CESC as the clearest survival context for RPSAP58 RNA expression.
This table summarizes RPSAP58 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPSAP58. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPSAP58 shows higher tumor expression in COAD, LIHC, UCEC, KIRC, KICH and LUAD. The COAD box plot shows higher RPSAP58 RNA expression in tumor versus normal tissue (log2 FC = +0.417, t-test p < 0.001).
This table shows molecular features associated with RPSAP58 in patient tissues and cancer cell lines. In patient samples, RPSAP58 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPSAP58 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
